Pharmaceutical compositions comprising a polynucleotide and...

Details Pharmaceutical compositions comprising a polynucleotide and... Pharmaceutical compositions comprising a polynucleotide and...

2006-02-21

2006-02-21

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C514S001000, C514S002600, C536S023100, C536S024100

Reexamination Certificate

active

07001890

ABSTRACT:
The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.

REFERENCES:
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5328987 (1994-07-01), Maliszewski
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5591825 (1997-01-01), McKnight et al.
patent: 5616489 (1997-04-01), Levy
patent: 5641486 (1997-06-01), Hinrichs et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5780448 (1998-07-01), Davis
patent: 5786189 (1998-07-01), Locht et al.
patent: 5834188 (1998-11-01), Harada et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5912168 (1999-06-01), Watson et al.
patent: 6057299 (2000-05-01), Henderson
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6653292 (2003-11-01), Krieg et al.
patent: 6727230 (2004-04-01), Hutcherson et al.
patent: 2001/0044416 (2001-11-01), McCluskie et al.
patent: 2002/0064515 (2002-05-01), Krieg et al.
patent: 2002/0091097 (2002-07-01), Bratzler et al.
patent: 2002/0156033 (2002-10-01), Bratzler et al.
patent: 2002/0164341 (2002-11-01), Davis et al.
patent: 2002/0165178 (2002-11-01), Schetter et al.
patent: 2002/0198165 (2002-12-01), Bratzler et al.
patent: 2003/0026782 (2003-02-01), Krieg et al.
patent: 2003/0026801 (2003-02-01), Weiner et al.
patent: 2003/0050261 (2003-03-01), Krieg et al.
patent: 2003/0050263 (2003-03-01), Krieg et al.
patent: 2003/0050268 (2003-03-01), Krieg et al.
patent: 2003/0055014 (2003-03-01), Bratzler
patent: 2003/0087848 (2003-05-01), Bratzler et al.
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0100527 (2003-05-01), Krieg et al.
patent: 2003/0104523 (2003-06-01), Lipford et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2003/0148316 (2003-08-01), Lipford et al.
patent: 2003/0148976 (2003-08-01), Krieg et al.
patent: 2003/0166001 (2003-09-01), Lipford
patent: 2003/0181406 (2003-09-01), Schetter et al.
patent: 2003/0191079 (2003-10-01), Krieg et al.
patent: 2003/0212026 (2003-11-01), Krieg et al.
patent: 2003/0224010 (2003-12-01), Davis et al.
patent: 2003/0232074 (2003-12-01), Lipford et al.
patent: 2004/0009949 (2004-01-01), Krieg
patent: 2004/0030118 (2004-02-01), Wagner et al.
patent: 2004/0053880 (2004-03-01), Krieg
patent: 2004/0067905 (2004-04-01), Krieg
patent: 2004/0087534 (2004-05-01), Krieg et al.
patent: 2004/0087538 (2004-05-01), Krieg et al.
patent: 2004/0092472 (2004-05-01), Krieg
patent: 2004/0106568 (2004-06-01), Krieg et al.
patent: 2004/0131628 (2004-07-01), Bratzler et al.
patent: 2004/0132685 (2004-07-01), Krieg et al.
patent: 2004/0142469 (2004-07-01), Krieg et al.
patent: 2004/0143112 (2004-07-01), Krieg et al.
patent: 2004/0147468 (2004-07-01), Krieg et al.
patent: 2004/0152649 (2004-08-01), Krieg
patent: 2004/0152656 (2004-08-01), Krieg et al.
patent: 2004/0152657 (2004-08-01), Krieg et al.
patent: 2004/0162258 (2004-08-01), Krieg et al.
patent: 2004/0162262 (2004-08-01), Krieg et al.
patent: 2004/0167089 (2004-08-01), Krieg et al.
patent: 2004/0171150 (2004-09-01), Krieg et al.
patent: 2004/0171571 (2004-09-01), Krieg et al.
patent: 2004/0181045 (2004-09-01), Krieg et al.
patent: 2004/0198688 (2004-10-01), Krieg et al.
patent: 0 092 574 (1983-11-01), None
patent: 0 468 520 (1992-01-01), None
patent: 0 302 758 (1994-03-01), None
patent: WO 91/12811 (1991-09-01), None
patent: WO 92/03456 (1992-03-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 92/21353 (1992-12-01), None
patent: WO 94/19945 (1994-09-01), None
patent: WO 95/05853 (1995-03-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO96/02560 (1996-02-01), None
patent: WO 96/12823 (1996-05-01), None
patent: WO 96/17960 (1996-06-01), None
patent: WO 96/35782 (1996-11-01), None
patent: WO97/28259 (1997-08-01), None
patent: WO 98/14210 (1998-04-01), None
patent: WO98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO98/55495 (1998-12-01), None
patent: WO99/51259 (1999-10-01), None
patent: WO99/56755 (1999-11-01), None
patent: WO99/58118 (1999-11-01), None
patent: WO99/61056 (1999-12-01), None
patent: WO00/06588 (2000-02-01), None
patent: WO00/14217 (2000-03-01), None
patent: WO00/67023 (2000-11-01), None
patent: WO01/22972 (2001-04-01), None
patent: WO01/22990 (2001-04-01), None
patent: WO 02/069369 (2002-09-01), None
patent: WO 2004/007743 (2004-01-01), None
patent: WO 2004/039829 (2004-05-01), None
Agrawal et al. Molecular Medicine Today, Feb. 2000, vol. 6, pp 72-81.
Pihl-Carey, I. BioWorld Today, Dec. 1999. vol. 10, PP 1-2.
Crooke, S. Antisense Res. and Application, 1998, Chap. 1, pp 1-50. Springer-Verlag, Pub.
Chirila et al. Biomaterials, 2002, vol. 23, pp 321-342.
Palu et al. J. Biotech. 1999. vol. 68, pp 1-13.
Branch, A. Trends in Biochem. Sci, Feb. 1998. vol. 358, pp 489-497.
Weiner, G. J. Leukocyte Biology, Oct. 2000, vol. 68, pp 455-462.
Blackshear, P. Toxicologic Path. 2001, vol. 29, No. 1, pp 105-116.
McCluskie, et al. Molecular Medicine, 1999, vol. 5, pp 287-300.
Cha, Y. et al. J. Biol. Chem. vol. 269, No. 7. pp. 5279-5287 (1994).
Dolganov, G. et al. Blood. vol. 87, No. 8, pp. 3316-3326 (1996).
Stanford, W. et al. Immunogenetics,. vol. 35, pp. 408-411 (1992).
Chu, R. et al. J. Exp. Med. vol. 186, No. 10, pp. 1623-1631 (1997).
Ballas ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.J. Immunol.Sep. 1, 1996;157(5):1840-5.
Bayever E et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.Antisense Res Dev.1993 Winter;3(4):383-90.
Boggs RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides.Antisense Nucleic Acid Drug Dev.Oct. 1997;7(5):461-71.
Branda RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides.J. Lab Clin Med.Sep. 1996;128(3):329-38.
Branda RF et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1.Biochem Pharmacol.May 25, 1993;45(10):2037-43.
Chace JH et al., Regulation of differentiation in CD5+ and conventional B cells. Sensitivity to LPS-induced differentiation and interferon-gamma-mediated inhibition of differentiation.Clin Immunol Immunopathol.Sep. 1993;68(3):327-32.
Chang YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements.J. Virol.Jan. 1990;64(1):264-77.
Chu RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.J Exp Med.Nov. 17, 1997;186(10):1623-31.
Cowdery JS et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides.J. Immunol.Jun. 15, 1996;156(12):4570-5.
Davis HL et al., CpG DNA is a potent enhancer o

Affiliated with

Also associated with

Rating

Pharmaceutical compositions comprising a polynucleotide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions comprising a polynucleotide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising a polynucleotide and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3656347